CASIMERSEN

CHEBI:CHEBI_749853

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
2480105
pharm_class
Increased Protein Synthesis [PE]
product_type
BULK INGREDIENT
marketing_category
BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
listing_expiration_date
20241231
dosage_form
INJECTION
marketing_start_date
20210225
package_marketing_start_date
25-FEB-21
route
INTRAVENOUS
active_ingredient_strength
1 g/g
labeler_name
Bachem Americas, Inc.
manufacturer_name
Sarepta Therapeutics, Inc.
nui
N0000009533
pharm_class_epc
Antisense Oligonucleotide [EPC]
pharm_class_cs
Oligonucleotides, Antisense [CS]
generic_name
casimersen
active_ingredient_name
CASIMERSEN
product_ndc
52416-095
spl_id
edc792f4-b3f3-3189-e053-2a95a90a76f9
package_ndc
52416-095-02
package_description
1 g in 1 BOTTLE, GLASS (52416-095-02)
brand_name
AMONDYS 45
brand_name_base
AMONDYS 45
application_number
NDA213026
unii
X8UHF7SX0R
spl_set_id
e9e5fd44-eeda-4580-bba1-a734828bbcc3
upc
0360923227022
pharm_class_pe
Increased Protein Synthesis [PE]
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class